The PEARRL project officially started on 1. May and will run for the next three years under the coordination of Dr Brendan Griffin from the University College Cork in Ireland.
PEARRL has received 3.9 million euro funding from the Horizon 2020 Framework Programme of the European Union. The main research objectives of the PEARRL research programme are to deliver novel bio-enabling formulations and new biopharmaceutics tools to predict their in vivo performance as a means to improve efficiency and cost-competitiveness in drug development, thus facilitating earlier access of patients to “breakthrough therapies”.
PEARRL will train 15 Early Stage Researchers (ESR) who can develop such new bio-enabling formulations (“better drugs”), biorelevant and in silico methods to predict formulation performance in vivo (“streamlined development”) and serve as communication bridgers between research and regulatory science (“accelerated approval”), thus bringing Pharma and regulatory objectives to fruition. PEARRL will benefit from the unique collaboration of leaders in Europe`s Pharma industry and academic excellence together with four of the most influential regulatory authorities in Europe; all with expertise working with innovative drug formulations and biopharmaceutics tools will benefit the PEARRL project.
PEARRL will train 15 Early Stage Researchers (ESR) who can develop such new bio-enabling formulations (“better drugs”), biorelevant and in silico methods to predict formulation performance in vivo (“streamlined development”) and serve as communication bridgers between research and regulatory science (“accelerated approval”), thus bringing Pharma and regulatory objectives to fruition. PEARRL will benefit from the unique collaboration of leaders in Europe`s Pharma industry and academic excellence together with four of the most influential regulatory authorities in Europe; all with expertise working with innovative drug formulations and biopharmaceutics tools will benefit the PEARRL project.
RSS Feed
